| Code | CSB-RA011614MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SSGJ-613, targeting interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B is produced primarily by activated macrophages and monocytes as an inactive precursor that requires cleavage by caspase-1 within the inflammasome complex to generate the mature, biologically active form. This cytokine plays a critical role in initiating and amplifying inflammatory cascades through induction of cyclooxygenase-2, nitric oxide synthase, and various acute phase proteins. Dysregulated IL1B signaling is implicated in numerous pathological conditions including autoinflammatory disorders, rheumatoid arthritis, type 2 diabetes, atherosclerosis, and various malignancies where it contributes to tumor progression and metastasis.
SSGJ-613 serves as the reference antibody for this biosimilar product, providing researchers with a cost-effective tool for investigating IL1B-mediated inflammatory pathways and disease mechanisms. This antibody is valuable for studies examining inflammasome activation, cytokine signaling networks, and therapeutic intervention strategies targeting inflammatory disorders.
There are currently no reviews for this product.